Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2018 Nov;40(1):671-679.
doi: 10.1080/0886022X.2018.1532909.

Hemoglobin targets for the anemia in patients with dialysis-dependent chronic kidney disease: a meta-analysis of randomized, controlled trials

Yuqiu Ye  1 , Hongyong Liu  2 , Yanbing Chen  3 , Yunqiang Zhang  2 , Shaomin Li  1 , Wentao Hu  1 , Rongqian Yang  4 , Zhesi Zhang  4 , Linsheng Lv  5 , Xun Liu  1   2
Affiliations
Meta-Analysis

Hemoglobin targets for the anemia in patients with dialysis-dependent chronic kidney disease: a meta-analysis of randomized, controlled trials

Yuqiu Ye et al. Ren Fail. 2018 Nov.

Abstract

Background: Anemia is extremely common among dialysis patients and underlies some of the symptoms associated with reduced kidney function, including fatigue, depression, reduced exercise tolerance, and dyspnea.

Objectives: A clearer cognition of the prognosistic impact of hemoglobin (Hb) or hematocrit (Hct) target for the outcomes of dialysis patients is urgent. This article aims to establish the suitable hemoglobin in order to provide clinical guidance.

Methods: MEDLINE, EmBase, the Cochrane Library and other databases were searched with both MeSH terms and keywords to gather randomized controlled trials that assessed all-cause mortality, cardiovascular events, fistula thrombosis, infectious diseases and transfusion among dialysis-dependent patients using erythropoiesis-stimulating agents. The meta-analysis was accomplished via Revman 5.3 version.

Findings: Totally, nine eligible studies were included, with study subjects involving 3228 patients. There was a significantly higher risk of fistula thrombosis without heterogeneity (RR 1.34, 95% CI 1.15-1.55; p < 0.05) in the higher Hb target group than in the lower Hb target group in the fixed effects model. However, no significant difference was found in all-cause mortality in the fixed effects model (RR 1.09, 95% CI 0.93-1.27; p = 0.30), cardiovascular events (RR 0.77, 95% CI 0.31-1.92; p = 0.58), infectious diseases (RR 0.69, 95% CI 0.24-1.96; p = 0.49) and transfusion (RR 0.92, 95% CI 0.42-1.99; p = 0.82) in the random effects model between the higher Hb target group and the lower Hb target group.

Discussion: The results favor lower Hb target. To target lower Hb target when treating dialysis patients with anemia may decrease the risk of fistula thrombosis without increasing the risk of death, cardiovascular events, infectious diseases and transfusion.

Keywords: Anemia; dialysis; meta-analysis; prognosis.

PubMed Disclaimer

Conflict of interest statement

No potential conflict of interest was reported by the authors.

Figures

Figure 1.
Figure 1.
Flow diagram of studies considered for inclusion.
Figure 2.
Figure 2.
Metagraph of all-cause mortality.
Figure 3.
Figure 3.
Metagraph of cardiovascular events.
Figure 4.
Figure 4.
Metagraph of treatment of infectious diseases.
Figure 5.
Figure 5.
Metagraph of fistula thrombosis.
Figure 6.
Figure 6.
Metagraph of transfusion.
Figure 7.
Figure 7.
The funnel plot of this study.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Bethesda M. USRDS annual data report: Epidemiology of kidney disease in the United States. United States Renal Data System, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. 2014:188–210.
    1. McGonigle RJ, Wallin JD, Shadduck RK, et al. . Erythropoietin deficiency and inhibition of erythropoiesis in renal insufficiency. Kidney international. 1984. Feb;25(2):437–44. - PubMed
    1. Kovesdy CP, Trivedi BK, Kalantar-Zadeh K, et al. . Association of anemia with outcomes in men with moderate and severe chronic kidney disease. Kidney Int. 2006. Feb;69(3):560–4. doi: 10.1038/sj.ki.5000105. - DOI - PubMed
    1. McClellan WM, Jurkovitz C, Abramson J.. The epidemiology and control of anaemia among pre-ESRD patients with chronic kidney disease. Eur J Clin Invest. 2005. Dec;35 Suppl 3:58–65. doi: 10.1111/j.1365-2362.2005.01532.x. - DOI - PubMed
    1. Singh AK. What is causing the mortality in treating the anemia of chronic kidney disease: erythropoietin dose or hemoglobin level? Curr Opin Nephrol Hypertens. 2010. Sep;19(5):420–4. doi: 10.1097/MNH.0b013e32833cf1d6. - DOI - PubMed

Publication types